CLDN5 and amyotrophic lateral sclerosis: In contrast, hBM-EPC treated ALS mice showed significant upregulation of ZO-1 (p = 0.001), occludin (p = 0.012), and claudin-5 (p = 0.039) protein levels versus media-treated ALS mice (Fig. 1).